Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Niagen Bioscience (NAGE) Other financing activities (2016 - 2025)

Niagen Bioscience (NAGE) has disclosed Other financing activities for 11 consecutive years, with $55000.0 as the latest value for Q4 2025.

  • On a quarterly basis, Other financing activities rose 34.15% to $55000.0 in Q4 2025 year-over-year; TTM through Dec 2025 was $67000.0, a 28.85% increase, with the full-year FY2025 number at $67000.0, up 28.85% from a year prior.
  • Other financing activities was $55000.0 for Q4 2025 at Niagen Bioscience, up from $6000.0 in the prior quarter.
  • In the past five years, Other financing activities ranged from a high of $75000.0 in Q4 2023 to a low of $3000.0 in Q2 2021.
  • A 5-year average of $34636.4 and a median of $41000.0 in 2024 define the central range for Other financing activities.
  • Biggest YoY gain for Other financing activities was 231.58% in 2021; the steepest drop was 80.0% in 2021.
  • Niagen Bioscience's Other financing activities stood at $63000.0 in 2021, then fell by 1.59% to $62000.0 in 2022, then increased by 20.97% to $75000.0 in 2023, then plummeted by 45.33% to $41000.0 in 2024, then soared by 34.15% to $55000.0 in 2025.
  • Per Business Quant, the three most recent readings for NAGE's Other financing activities are $55000.0 (Q4 2025), $6000.0 (Q2 2025), and $6000.0 (Q1 2025).